Barclays
EDIT icon

Barclays’s Editas Medicine EDIT Stock Holding History

Barclays’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$360K Sell
145,602
-130,660
-47% -$277K ﹤0.01% 3371
2025
Q4 		$566K Buy
276,262
+89,212
+48% +$258K ﹤0.01% 3772
2025
Q3 		$649K Sell
187,050
-12,480
-6% -$34.8K ﹤0.01% 3634
2025
Q2 		$439K Buy
199,530
+58,346
+41% +$95.5K ﹤0.01% 3827
2025
Q1 		$164K Sell
141,184
-40,054
-22% -$58.9K ﹤0.01% 4153
2024
Q4 		$230K Buy
181,238
+2,731
+2% +$6.96K ﹤0.01% 4241
2024
Q3 		$609K Buy
178,507
+56,986
+47% +$248K ﹤0.01% 3651
2024
Q2 		$568K Sell
121,521
-23,202
-16% -$131K ﹤0.01% 2970
2024
Q1 		$1.07M Sell
144,723
-134,714
-48% -$1.12M ﹤0.01% 3063
2023
Q4 		$2.83M Buy
279,437
+4,421
+2% +$38.8K ﹤0.01% 2625
2023
Q3 		$2.15M Sell
275,016
-24,270
-8% -$208K ﹤0.01% 1849
2023
Q2 		$2.46M Buy
299,286
+24,164
+9% +$211K ﹤0.01% 1750
2023
Q1 		$1.99M Sell
275,122
-165,279
-38% -$1.47M ﹤0.01% 2205
2022
Q4 		$3.91M Buy
440,401
+140,174
+47% +$1.54M ﹤0.01% 1797
2022
Q3 		$3.67M Buy
300,227
+278,208
+1,263% +$4.33M ﹤0.01% 1355
2022
Q2 		$261K Sell
22,019
-9,313
-30% -$125K ﹤0.01% 3290
2022
Q1 		$596K Sell
31,332
-63,162
-67% -$1.17M ﹤0.01% 2774
2021
Q4 		$2.51M Buy
94,494
+3,755
+4% +$129K ﹤0.01% 2229
2021
Q3 		$3.73M Buy
90,739
+27,145
+43% +$1.49M ﹤0.01% 1831
2021
Q2 		$3.6M Sell
63,594
-40,923
-39% -$1.51M ﹤0.01% 1793
2021
Q1 		$4.39M Buy
104,517
+80,652
+338% +$4.59M ﹤0.01% 1622
2020
Q4 		$1.67M Sell
23,865
-23,093
-49% -$949K ﹤0.01% 2383
2020
Q3 		$1.32M Sell
46,958
-3,973
-8% -$129K ﹤0.01% 2448
2020
Q2 		$1.51M Buy
50,931
+5,820
+13% +$152K ﹤0.01% 2387
2020
Q1 		$896K Sell
45,111
-28,527
-39% -$719K ﹤0.01% 3067
2019
Q4 		$2.18M Buy
73,638
+18,260
+33% +$456K ﹤0.01% 2906
2019
Q3 		$1.26M Buy
55,378
+22,979
+71% +$569K ﹤0.01% 3434
2019
Q2 		$802K Buy
32,399
+18,653
+136% +$445K ﹤0.01% 3912
2019
Q1 		$336K Sell
13,746
-19,618
-59% -$444K ﹤0.01% 4428
2018
Q4 		$759K Buy
33,364
+15,183
+84% +$413K ﹤0.01% 3404
2018
Q3 		$579K Buy
18,181
+3,994
+28% +$129K ﹤0.01% 4145
2018
Q2 		$509K Sell
14,187
-25,552
-64% -$905K ﹤0.01% 3939
2018
Q1 		$1.32M Buy
39,739
+23,426
+144% +$835K ﹤0.01% 2895
2017
Q4 		$502K Buy
16,313
+3,510
+27% +$88.4K ﹤0.01% 3828
2017
Q3 		$307K Buy
12,803
+12,546
+4,882% +$239K ﹤0.01% 4052
2017
Q2 		$4K Sell
257
-1,362
-84% -$24.5K ﹤0.01% 6275
2017
Q1 		$37K Sell
1,619
-487
-23% -$10.1K ﹤0.01% 5497
2016
Q4 		$34K Buy
2,106
+1,962
+1,363% +$29.8K ﹤0.01% 5369
2016
Q3 		$2K Buy
+144
New +$2.95K ﹤0.01% 6227
2016
Q2 		– Sell
-24,240
Closed -$824K – 6378
2016
Q1 		$824K Buy
+24,240
New +$637K ﹤0.01% 2696

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays's EDIT Position: Q1 2026 in Review

Barclays reduced its Editas Medicine (EDIT) stake by 47% in Q1 2026, selling an estimated $277K and leaving 145,602 shares worth $360K. The position accounts for ﹤0.01% of the portfolio, ranked #3371.

Barclays first reported a position in EDIT in Q1 2016 and has held it in 40 quarters since. The position peaked at $4.39M in Q1 2021. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Barclays held 145,602 shares of Editas Medicine worth $360K as of Q1 2026.
  • Barclays sold 130,660 Editas Medicine shares in Q1 2026, an estimated $277K.
  • Editas Medicine made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3371 holding.
  • Barclays first reported a position in Editas Medicine in Q1 2016 and has held it in 40 quarters since.
  • Barclays's Editas Medicine position peaked at $4.39M in Q1 2021.
  • 207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.